The study will investigate the benefits of offering surgeons instantaneous microscopic images of target tissue during open and laparoscopic procedures to remove cancerous tumors, while offering valuable feedback on the Cellvizio prototype probes developed for use in various procedures, including colorectal, ear, nose and throat (ENT) and gynecologic surgery.
With Prof. Cadière, Mauna Kea Technologies will explore complementary routes to those currently under investigation as part of the Persee project, a collaborative effort with a French start-up company specialized in robotic surgery solutions (Endocontrol), an academic laboratory (ISIR) and two leading French hospitals (Institut Mutualiste Montsouris and Institut Gustave Roussy).
The Persee initiative has been funded by OSEO's Strategic Industrial Innovation program since its inception in 2010. To date, several prototypes for surgical Cellvizio probes have been developed and are being validated in preclinical conditions in preparation of a clinical trial in 2013.
Mauna Kea Technologies is a global medical device company. The company researches and develops tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Cellvizio can be used with almost any endoscope, Mauna Kea reported.